These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 30877216

  • 1. Effects of Sarilumab on Rheumatoid Arthritis as Reported by Patients Using the Rheumatoid Arthritis Impact of Disease Scale.
    Gossec L, Strand V, Proudfoot C, Chen CI, Guillonneau S, Kimura T, van Hoogstraten H, Mangan E, Reaney M.
    J Rheumatol; 2019 Oct; 46(10):1259-1267. PubMed ID: 30877216
    [Abstract] [Full Text] [Related]

  • 2. Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis.
    Strand V, Gossec L, Proudfoot CWJ, Chen CI, Reaney M, Guillonneau S, Kimura T, van Adelsberg J, Lin Y, Mangan EK, van Hoogstraten H, Burmester GR.
    Arthritis Res Ther; 2018 Jun 19; 20(1):129. PubMed ID: 29921318
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial.
    Burmester GR, Lin Y, Patel R, van Adelsberg J, Mangan EK, Graham NM, van Hoogstraten H, Bauer D, Ignacio Vargas J, Lee EB.
    Ann Rheum Dis; 2017 May 19; 76(5):840-847. PubMed ID: 27856432
    [Abstract] [Full Text] [Related]

  • 4. Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension.
    Burmester GR, Strand V, Rubbert-Roth A, Amital H, Raskina T, Gómez-Centeno A, Pena-Rossi C, Gervitz L, Thangavelu K, St John G, Boklage S, Genovese MC.
    RMD Open; 2019 May 19; 5(2):e001017. PubMed ID: 31673415
    [Abstract] [Full Text] [Related]

  • 5. Association of High Serum Interleukin-6 Levels With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab From Adalimumab or Methotrexate in a Post Hoc Analysis.
    Boyapati A, Schwartzman S, Msihid J, Choy E, Genovese MC, Burmester GR, Lam G, Kimura T, Sadeh J, Weinreich DM, Yancopoulos GD, Graham NMH.
    Arthritis Rheumatol; 2020 Sep 19; 72(9):1456-1466. PubMed ID: 32343882
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor α inhibitors: systematic literature review and network meta-analyses.
    Choy E, Freemantle N, Proudfoot C, Chen CI, Pollissard L, Kuznik A, Van Hoogstraten H, Mangan E, Carita P, Huynh TM.
    RMD Open; 2019 Sep 19; 5(1):e000798. PubMed ID: 30886733
    [Abstract] [Full Text] [Related]

  • 7. High levels of interleukin-6 in patients with rheumatoid arthritis are associated with greater improvements in health-related quality of life for sarilumab compared with adalimumab.
    Strand V, Boklage SH, Kimura T, Joly F, Boyapati A, Msihid J.
    Arthritis Res Ther; 2020 Oct 20; 22(1):250. PubMed ID: 33081825
    [Abstract] [Full Text] [Related]

  • 8. Association between low hemoglobin, clinical measures, and patient-reported outcomes in patients with rheumatoid arthritis: results from post hoc analyses of three phase III trials of sarilumab.
    Rubbert-Roth A, Furst DE, Fiore S, Praestgaard A, Bykerk V, Bingham CO, Charles-Schoeman C, Burmester G.
    Arthritis Res Ther; 2022 Aug 25; 24(1):207. PubMed ID: 36008838
    [Abstract] [Full Text] [Related]

  • 9. Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial.
    Strand V, Kosinski M, Chen CI, Joseph G, Rendas-Baum R, Graham NM, van Hoogstraten H, Bayliss M, Fan C, Huizinga T, Genovese MC.
    Arthritis Res Ther; 2016 Sep 06; 18(1):198. PubMed ID: 27600829
    [Abstract] [Full Text] [Related]

  • 10. Economic Evaluation of Sarilumab in the Treatment of Adult Patients with Moderately-to-Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs.
    Muszbek N, Proudfoot C, Fournier M, Chen CI, Kuznik A, Kiss Z, Gal P, Michaud K.
    Adv Ther; 2019 Jun 06; 36(6):1337-1357. PubMed ID: 31004324
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies.
    Genovese MC, Fleischmann R, Kivitz A, Lee EB, van Hoogstraten H, Kimura T, St John G, Mangan EK, Burmester GR.
    Arthritis Res Ther; 2020 Jun 10; 22(1):139. PubMed ID: 32522251
    [Abstract] [Full Text] [Related]

  • 12. Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes.
    Gabay C, Burmester GR, Strand V, Msihid J, Zilberstein M, Kimura T, van Hoogstraten H, Boklage SH, Sadeh J, Graham NMH, Boyapati A.
    Arthritis Res Ther; 2020 Apr 07; 22(1):70. PubMed ID: 32264972
    [Abstract] [Full Text] [Related]

  • 13. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan.
    Tanaka Y, Wada K, Takahashi Y, Hagino O, van Hoogstraten H, Graham NMH, Kameda H.
    Arthritis Res Ther; 2019 Mar 20; 21(1):79. PubMed ID: 30894208
    [Abstract] [Full Text] [Related]

  • 14. Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors.
    Fleischmann R, van Adelsberg J, Lin Y, Castelar-Pinheiro GD, Brzezicki J, Hrycaj P, Graham NM, van Hoogstraten H, Bauer D, Burmester GR.
    Arthritis Rheumatol; 2017 Feb 20; 69(2):277-290. PubMed ID: 27860410
    [Abstract] [Full Text] [Related]

  • 15. Sarilumab: A Review in Moderate to Severe Rheumatoid Arthritis.
    Lamb YN, Deeks ED.
    Drugs; 2018 Jun 20; 78(9):929-940. PubMed ID: 29931592
    [Abstract] [Full Text] [Related]

  • 16. Sarilumab monotherapy or in combination with non-methotrexate disease-modifying antirheumatic drugs in active rheumatoid arthritis: A Japan phase 3 trial (HARUKA).
    Kameda H, Wada K, Takahashi Y, Hagino O, van Hoogstraten H, Graham N, Tanaka Y.
    Mod Rheumatol; 2020 Mar 20; 30(2):239-248. PubMed ID: 31268376
    [Abstract] [Full Text] [Related]

  • 17. Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial.
    Huizinga TW, Fleischmann RM, Jasson M, Radin AR, van Adelsberg J, Fiore S, Huang X, Yancopoulos GD, Stahl N, Genovese MC.
    Ann Rheum Dis; 2014 Sep 20; 73(9):1626-34. PubMed ID: 24297381
    [Abstract] [Full Text] [Related]

  • 18. Interleukin-6 receptor blockade or TNFα inhibition for reducing glycaemia in patients with RA and diabetes: post hoc analyses of three randomised, controlled trials.
    Genovese MC, Burmester GR, Hagino O, Thangavelu K, Iglesias-Rodriguez M, John GS, González-Gay MA, Mandrup-Poulsen T, Fleischmann R.
    Arthritis Res Ther; 2020 Sep 09; 22(1):206. PubMed ID: 32907617
    [Abstract] [Full Text] [Related]

  • 19. Sarilumab: Review of a Second IL-6 Receptor Antagonist Indicated for the Treatment of Rheumatoid Arthritis.
    Boyce EG, Rogan EL, Vyas D, Prasad N, Mai Y.
    Ann Pharmacother; 2018 Aug 09; 52(8):780-791. PubMed ID: 29482351
    [Abstract] [Full Text] [Related]

  • 20. Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment.
    Genovese MC, van der Heijde D, Lin Y, St John G, Wang S, van Hoogstraten H, Gómez-Reino JJ, Kivitz A, Maldonado-Cocco JA, Seriolo B, Stanislav M, Burmester GR.
    RMD Open; 2019 Aug 09; 5(2):e000887. PubMed ID: 31452928
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.